Skip to main content

Table 1 Comparisons of characteristics between chemotherapy group and control group in original 12,334 HR-positive, Her-2-negative, pT1b-c/N0–1/M0 ILC patients

From: Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

   Control (n = 10,549) Chemotherapy (n = 1785) Statistical value P bias t-test for bias P
Age (years) < 40 59 (0.56%) 47 (2.63%) χ2 = 576.457 0.001 −62.1 −24.37 0.001
40–49 1088 (10.31%) 392 (21.96%)
50–59 2316 (21.95%) 605 (33.89%)
60–69 3896 (36.93%) 557 (31.20%)
70–79 3190 (30.24%) 184 (10.31%)
Race Black 868 (8.23%) 174 (9.75%) χ2 = 4.627 0.099 −4.6 −1.81 0.071
White 8966 (84.99%) 1495 (83.75%)
Other 715 (6.78%)) 116 (6.50%))
Tumor Ib 3455 (32.75%) 374 (20.95%) χ2 = 99.294 0.001 26.9 10.00 0.001
Ic 7094 (67.25%) 1411 (79.05%)
LN N0 9308 (88.24%) 895 (50.14%) χ2 = 1.6e+ 03 0.001 90.6 42.10 0.001
N1 1241 (11.76%) 890 (49.86%)
Grade I 3618 (34.30%) 430 (24.09%) z = −10.373 0.001 27.6 10.87 0.001
II 6472 (61.35%) 1188 (66.55%)
III 459 (4.35%) 167 (9.36%)
Radiotherapy No 4774 (45.26%) 883 (49.47%) χ2 = 10.910 0.001 −8.4 −3.30 0.001
Yes 5775 (54.74%) 902 (50.53%)
Surgery No surgery 177 (1.68%) 36 (2.02%) χ2 = 190.161 0.001 31.5 12.61 0.001
BCS 6777 (64.24%) 842 (47.17%)
Mastectomy 3595 (34.08%) 907 (50.81%)